Receptor.AI, a U.S.-based TechBio company, is reshaping preclinical drug discovery through its advanced generative AI platforms. With a strong technology stack, proven results, and collaborations with Japanese pharmaceutical leaders such as Ono Pharmaceutical, it exemplifies the growing shift toward computational and data-driven R&D in biotech.

At the heart of Receptor.AI’s success is its multiplatform AI ecosystem, designed to accelerate the identification and optimization of novel therapeutics. This modular, end-to-end infrastructure addresses some of the most pressing challenges in drug discovery:

• Small Molecule Platform: De novo AI-driven design of small molecules by leveraging key interactions related to biological activity with optimization of over 80 drug properties.
• Peptides Platform: AI-guided de novo design and optimization of linear and cyclic peptides against challenging targets, including “undruggable” protein-protein interactions.
• Induced Proximity Platform: Engineering ternary complexes to transform structurally unresolved native and induced PPIs into druggable targets.

Built on extensive experience and over 40 successful joint discovery projects, Receptor.AI’s multiplatform ecosystem empowers researchers to design small molecules, peptides, and induced proximity agents with unprecedented speed and accuracy. By focusing on validated, modular workflows that integrate seamlessly into existing R&D processes, Receptor.AI has become a trusted partner to big pharma companies and academic institutions worldwide. For further information, please visit the company’s website at receptor.ai. 

While the company continues to deepen its presence in North Americaand Europe, Asia represents a strategic frontier. In March 2025, Receptor.AI initiated a research collaboration with OnoPharmaceutical, a leader in Japan’s innovation ecosystem. Thepartnership exemplifies Receptor.AI’s commitment to fosteringhigh-impact, AI-enabled drug discovery across global therapeuticlandscapes.

“Our goal is to empower scientists with tools that not only accelerate discovery but raise the ceiling on what is therapeutically possible,” said Alan Nafiiev, CEO of Receptor.AI. “Japan has a strong tradition of innovation in life sciences, and we are excited to contribute AI capabilities that can complement and enhance this strength.”